| Description |
1 online resource (54 pages) : illustrations |
| Series |
Oxford American pocket notes |
|
Oxford American pocket notes.
|
| Contents |
Cover; Table of Contents; Introduction; Antiestrogen Therapies; Aromatase Inhibitors (AI's); Selective Estrogen Receptor Modulators (SERM's) and Estrogen-Receptor Downregulators (ERD's); Chemotherapeutic Agents-Microtubule Targeting Agents; Taxanes; Ixabepilone; Eribulin Mesylate; HER2 Directed Therapies for Metastatic Breast Cancer; Trastuzumab; Trastuzumab-Refactory Breast Cancer; Investigational Agents; HER2 Directed Therapy for Early Stage Breast Cancer; Angiogenesis Inhibitors in Breast Cancer; Bevacizumab; VEGFR Inhibitors; PARP Inhibitors; Emerging Areas; References |
| Summary |
The development of monoclonal antibodies and other inhibitors of specific molecules, fully utilizing the insights learned from molecular techniques such as comparative microarrays and protein expression patterns, has led to the development and FDA approval of several agents for the treatment of breast cancer, such as trastuzamab (Herceptin, targeting HER-2 positive tumors) and lapatinib (Tykerb, targeting tumors with mutated/overexpressed EGFR 1 and 2). Other agents specifically targeting the estrogen receptor, the aromatose pathway and microtubule dynamics, fulvestrant (Faslodex, targeting th |
| Bibliography |
Includes bibliographical references |
| Notes |
English |
|
Print version record |
| Subject |
Breast -- Cancer -- Treatment -- Handbooks, manuals, etc
|
|
Drug targeting -- Handbooks, manuals, etc
|
|
Drug Delivery Systems
|
|
Breast Neoplasms -- drug therapy
|
|
HEALTH & FITNESS -- Diseases -- Cancer.
|
|
MEDICAL -- Oncology.
|
|
Breast -- Cancer -- Treatment
|
|
Drug targeting
|
| Genre/Form |
Handbooks and manuals
|
| Form |
Electronic book
|
| LC no. |
2012419417 |
| ISBN |
9780199749751 |
|
0199749752 |
|
1280699094 |
|
9781280699092 |
|
9786613676061 |
|
6613676063 |
|
